Investigation of the Effect of Systemic Steroids on Treatment and Prevention of Recurrent Tracheal Stenosis in Postoperative Patients
Primary Purpose
Tracheal Stenosis
Status
Completed
Phase
Phase 4
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Prednisolone
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Tracheal Stenosis
Eligibility Criteria
Inclusion criteria:
- Post-operative resection anastomosis patients.
- Age more than 10 years old.
- no severe tension in surgery by the opinion of surgeon.
Exclusion Criteria:
- Pregnancy
- History of significant medical condition not controlled by medicines. Ex: cardiovascular diseases, endocrine impairments and etc.
- Weight is ≥200% ideal body weight
- Severe chronic liver disease
- immunosuppression including HIV+ status, history of bone marrow or solid organ transplantation, current malignancy, neutropenia
- Fungal systemic infection
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Prednisolone
Placebo
Arm Description
dose: 15 mg per day(divided 5 mg TDS) dosage form: tablet duration administration: 30 days
placebo given to patient: 3 tablet (divided TDS) dosage form: tablet duration administration: 30 days
Outcomes
Primary Outcome Measures
Completely wound healing.
achieved by fiber optic bronchoscopy (FOB) and a surgeon judged that the patients were with out any sign of clinical symptoms of upper respiratory tract stenosis postoperatively and anastomosis site was with out any presence of stenosis (fibrous tissue), granulation tissue formation and inflamed mucosa.
Secondary Outcome Measures
Granulation tissue formation without visible dehiscence
achieved by fiber optic bronchoscopy (FOB) and a surgeon judged about production of fibrotic and excess granulation tissue at the site of anastomosis during FOB.
Full Information
NCT ID
NCT02855502
First Posted
April 17, 2016
Last Updated
April 2, 2017
Sponsor
National Research Institute of Tuberculosis and Lung Disease, Iran
1. Study Identification
Unique Protocol Identification Number
NCT02855502
Brief Title
Investigation of the Effect of Systemic Steroids on Treatment and Prevention of Recurrent Tracheal Stenosis in Postoperative Patients
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
November 2014 (undefined)
Primary Completion Date
October 2016 (Actual)
Study Completion Date
December 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Research Institute of Tuberculosis and Lung Disease, Iran
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
tracheal stenosis is the result of abnormal wound-healing processes leading to hypertrophic scar formation and obstruction of the airway lumen by excess granulation tissue. This process is progressive so treatment and prevention is essential. Resection-anastomosis of the trachea is becoming the standard of care in many centers and gives the most consistent results in both adult and pediatric patients. But recurrence stenosis, re-granulation and re-inflammation are probable. This study aimed to assess the efficacy of systemic prednisolone on prevention of recurrent tracheal stenosis after surgery.
Detailed Description
Tracheal stenosis affects 4-13% of adults and occurs in 1-8% of neonates after prolonged intubation in United States. The causes of adults' tracheal stenosis include trauma, chronic inflammatory diseases, benign neoplasm, malignant neoplasm and collagen vascular diseases. The most common cause of tracheal stenosis continues to be trauma, which can be internal (prolonged endotracheal intubation, tracheostomy, flame, burn injury) or external (neck trauma). Approximately 90% of chronic subglottic stenosis in children and adults results from endotracheal intubation or tracheostomy and about 10% results from other causes.
The resection anastomosis is the most effective treatment to cure this condition. The other treatments are mechanical dilation (dilators, rigid bronchoscopes), stents, laser co2, diode, and cold knife. But they are not as effective as resection anastomosis. Rigid bronchoscopes or dilators may shear the mucosa leading to further damage. Resection of all damaged segments of the airway, approximation and anastomosis of the two intact ends by means of fine synthetic absorbable sutures with minimum tension. Steroids with anti-inflammatory effect widely use as first line therapy for this condition.
Patients who underwent resection anastomosis during 2014-2016 for treatment of post-intubation tracheal stenosis will be included in this study. Systemic prednisolone will be used for treatment and prevention of recurrent tracheal stenosis in post-operative patients. Post-operative patients will divide in two groups, one of them will receive prednisolone and the other will receive placebo for 30 days. The results will be compared by bronchoscopy (FOB or rigid) after 30 days.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tracheal Stenosis
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Prednisolone
Arm Type
Active Comparator
Arm Description
dose: 15 mg per day(divided 5 mg TDS) dosage form: tablet duration administration: 30 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
placebo given to patient: 3 tablet (divided TDS) dosage form: tablet duration administration: 30 days
Intervention Type
Drug
Intervention Name(s)
Prednisolone
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Completely wound healing.
Description
achieved by fiber optic bronchoscopy (FOB) and a surgeon judged that the patients were with out any sign of clinical symptoms of upper respiratory tract stenosis postoperatively and anastomosis site was with out any presence of stenosis (fibrous tissue), granulation tissue formation and inflamed mucosa.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Granulation tissue formation without visible dehiscence
Description
achieved by fiber optic bronchoscopy (FOB) and a surgeon judged about production of fibrotic and excess granulation tissue at the site of anastomosis during FOB.
Time Frame
30 days
Other Pre-specified Outcome Measures:
Title
inflammation
Description
achieved by fiber optic bronchoscopy (FOB) and surgeon judged the principal etiology of recurrence of an inflammatory process in the anastomosis site which results in development of fibrotic tissue.
Time Frame
30 days
Title
Partial and complete dehiscence with or without infection
Description
patients referent hospital emergency, cause of breathing problems and re intubation must needed.
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Post-operative resection anastomosis patients.
Age more than 10 years old.
no severe tension in surgery by the opinion of surgeon.
Exclusion Criteria:
Pregnancy
History of significant medical condition not controlled by medicines. Ex: cardiovascular diseases, endocrine impairments and etc.
Weight is ≥200% ideal body weight
Severe chronic liver disease
immunosuppression including HIV+ status, history of bone marrow or solid organ transplantation, current malignancy, neutropenia
Fungal systemic infection
Facility Information:
City
Tehran
Country
Iran, Islamic Republic of
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Investigation of the Effect of Systemic Steroids on Treatment and Prevention of Recurrent Tracheal Stenosis in Postoperative Patients
We'll reach out to this number within 24 hrs